西妥昔单抗联合紫杉醇+顺铂新辅助化疗对食管癌细胞增殖及侵袭活力的影响

Effect of cetuximab combined with paclitaxel+ cisplatin neoadjuvant chemotherapy on esophageal cancer cell proliferation and invasion

目的:探讨西妥昔单抗联合紫杉醇+顺铂新辅助化疗对食管癌细胞增殖及侵袭活力的影响。方法:收集2015年1月~2016年12月间在本院接受治疗的食管癌患者62例,按照随机数表法分为对照组、观察组,各31例。对照组患者接受紫杉醇+顺铂新辅助化疗+手术,观察组患者接受西妥昔单抗联合紫杉醇+顺铂新辅助化疗+手术,对比化疗前后,两组患者肿瘤组织中增殖、侵袭基因表达量的差异。结果:化疗前,两组患者肿瘤组织中增殖、侵袭基因表达量的差异无统计学意义(P>0.05)。化疗后,观察组患者肿瘤组织中促增殖基因FOXA1、ABCE1、USP39、Nestin mRNA的表达量低于对照组患者肿瘤组织(P<0.05);抗增殖基因PETN、KLF4、TSLC1、AnnexinA2mRNA的表达量高于对照组患者肿瘤组织(P<0.05);促侵袭基因γ-synuclein、CXCR4、Snail mRNA的表达量低于对照组患者肿瘤组织(P<0.05);抗侵袭基因CIAPIN1、Fez、Lrig1 mRNA的表达量高于对照组患者肿瘤组织(P<0.05)。结论:西妥昔单抗联合紫杉醇+顺铂新辅助化疗可有效抑制食管癌细胞的恶性程度,抑制其增殖侵袭。

Objective：To study the effect of cetuximab combined with paclitaxel＋ cisplatin neoadjuvant chemotherapy on esophageal cancer cell proliferation and invasion.Methods：A total of 62 patients with esophageal cancer who were treated in the hospital between January 2015 and December 2016 were collected and divided into control group and observation group according to random number table,31 cases in each group.Control group patients received paclitaxel＋ cisplatin neoadjuvant chemotherapy＋ surgery,and observation group patients accepted cetuximab combined with paclitaxel＋cisplatin neoadjuvant chemotherapy＋ surgery.The differences in proliferation and invasion gene expression in the tumor tissue were compared between two groups of patients before and after chemotherapy.Results：Before chemotherapy,differences in proliferation and invasion gene expression in tumor tissue were not statistically significant between two groups of patients（P〈0.05）.After chemotherapy,pro-proliferation genes FOXA1,ABCE1,USP39 and Nestin mRNA expression in tumor tissue of observation group were lower than those of control group;anti-proliferation genes PETN,KLF4,TSLC1 and AnnexinA2 mRNA expression were higher than those of control group;pro-invasion genesγ-synuclein,CXCR4 and Snail mRNA expression were lower than those of control group;anti-invasion genes CIAPIN1,Fez and Lrig1 mRNA expression were significantly higher than those of control group（P〈0.05）.Conclusion：Cetuximab combined with paclitaxel＋cisplatin neoadjuvant chemotherapy can effectively inhibit the malignant degree of esophageal cancer cells and inhibit its proliferation and invasion.